tbuckley/cabot-search huggingface dataset:
La grippe sous surveillance étroite
Authors: M. S. Vilayleck
Journal: Eurosurveillance (2002)

Une epidemie importante de syndromes grippaux est survenue a Madagascar au cours des mois de juillet-aout 2002. Face a l’augmentation rapide du nombre de cas sur une courte periode, les autorites sanitaires ont craint l’apparition d’une nouvelle souche virale particulierement virulente, ce qui a declenche une reponse internationale immediate. Une equipe internationale de l’OMS a assiste les autorites sanitaires locales dans l’investigation et le controle de l’epidemie. Les resultats preliminaires ont heureusement revele que la souche impliquee etait connue, de type A/Panama/2007/99 en circulation dans le monde depuis plusieurs annees.
Rates of CR with and without Measurable Residual Disease after Induction Treatment with "7+3" or Azacitidine/Decitabine for Newly-Diagnosed AML
Authors: Todd Yezefski, Roland B. Walter, Pamela S. Becker, Paul C. Hendrie, Vivian Oehler, Mary-Elizabeth M. Percival, Elihu H. Estey
Journal: Blood (2016)
Retrospective analysis of the therapeutic efficacy of platinum/etoposide schedules in the treatment of advanced poor differentiated neuroendocrine carcinomas of the lung
Authors: F. Chillari, G. Blanco, A. Russo, I. Puliafito, S. Munaò, A. Battaglia, T. Franchina, L. Castorina, D. Giuffrida, V. Adamo
Journal: Annals of Oncology (2017)
American Heart Association Principles on the Accessibility and Affordability of Drugs and Biologics
Authors: Elliott M. Antman, Mark A. Creager, Steven R. Houser, John J. Warner, Madeleine Konig
Journal: Circulation (2017)

Net US spending on pharmaceuticals reached $309.5 billion in 2015, an 8.5% increase from the year before, and is expected to reach between $370 and $400 billion by 2020. These current and projected levels have raised serious concerns by policy makers, providers, payers, and patient groups that they are unsustainable and threaten the affordability of and accessibility to much-needed therapies for patients. Two trends related to drugs/biologics and generic drugs/biosimilars underlie this overall increase in spending. First, the market entry prices of innovator pharmaceutical products, or brand drugs and biologics, are at levels that some assessments consider unaffordable to the healthcare system. Second, prices for some established generic drugs such as digoxin and captopril have seen sharp and rapid increases. As an evidence-based patient advocacy organization dedicated to improving the cardiovascular health of all Americans, the American Heart Association has a unique role in advocating for treatments, including medicines that are available, affordable, and accessible to patients. This advisory serves to lay out a set of principles that will guide association engagement in pursuit of this goal.
NIMG-84. TUMOR LOCATION IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1,458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS
Authors: Benjamin Ellingson, Lauren Abrey, Sarah Nelson, Josep Garcia, Olivier Chinot, Frank Saran, Ryo Nishikawa, Roger Henriksson, Warren Mason, Wolfgang Wick, Nicholas Butowski, Keith Ligon, Elizabeth Gerstner, Howard Colman, Jennie Taylor, Isabel Arrillaga-Romany, Ray Huang, Whitney Pope, David Reardon, Tracy Batchelor, Patrick Y Wen, Michael Prados, Timothy F Cloughesy
Journal: Neuro-Oncology (2017)

The prognostic significance of tumor location in newly diagnosed GBM (NDGBM) remains provocative and poorly understood. In this study we pooled imaging data in >1,400 NDGBM patients from international multicenter clinical trials, single institution databases, and multicenter clinical trial consortiums to identify relationships between tumor location on OS, independent of clinical and genetic or molecular characteristics. Data from 1,458 newly diagnosed GBM patients from the following sources were included in our imaging database: 1) a single institution database from UCLA (N=398; Training Set 1); 2) patients treated within the Ben and Cathy Ivy Foundation for Early Phase Clinical Trials Consortium (N=262; Training Set 2); and 3) AVAglio – an international phase III trial comparing chemoradiation plus bevacizumab (N=404) vs. placebo (N=394) used as a validation set. Voxel-wise statistical parameter mapping (SPM) using multivariate Cox regression was performed to determine the influence of tumor location on OS. Covariates included in the SPM model consisted of clinical variables (age, gender, etc.), MGMT status, molecular phenotype (when available), initial treatment including extent of resection, and RPA class. Separate maps were created for all three datasets independently (UCLA, Ivy, and AVAglio) to validate the reproducibility of the SPMs. Data suggest tumors localized to the left or right parietal lobe, left insula, left or right thalamus, and left frontal lobe have an elevated hazard ratio (HR>1.5, P<0.05), whereas tumors localized to the right frontal lobe or left or right anterior cingulate had a significantly lower risk of death (HR<0.8, P<0.05), independent of other covariates. Frontal lobe and anterior cingulate regions were associated with the proneural molecular subtype and younger patients, and mesenchymal tumors and tumors in older patients were localized more posterior. Results from the current study further support the hypotheses that tumor location significantly influences survival in patients with NDGBM.
DDIS-23. A COMBINATORIAL TREATMENT USING A CK2 INHIBITOR, CX-4945, AND TMZ DECREASED MEDULLOBLASTOMA TUMORIGENESIS
Authors: Ryan Nitta, Gigi Nwagbo, Benjamin Jin, Gordon Li
Journal: Neuro-Oncology (2017)

Medulloblastoma (MB) is the most common malignant pediatric brain tumor. While surgery, craniospinal irradiation, and chemotherapy have resulted in a cure rate of 70–75%, the surviving patients are afflicted with neurocognitive impairment, endocrine dysfunction, and a severe decrease in quality of life. Consequently, better and more effective treatments are needed to treat these young patients. Casein kinase 2 (CK2) is an intriguing therapeutic target for MB because it is dysregulated in all the MB molecular subgroups and patients with high CK2 expression have a significantly worse prognosis. To elucidate the role of CK2 in MB we transduced multiple MB cell lines with CK2 isoforms. We discovered that a CK2 isoform, CK2alpha, increased MB tumorigenesis in both the SHH and Grade 3 molecular subgroups, while knocking down its expression ameliorated MB growth. We also found that CK2 can regulate MB tumorigenesis through beta-catenin and potentially GLI1. We extended our analysis to a CK2 inhibitor, CX-4945, which is currently undergoing phase I/II clinical trials. Treatment with CX-4945 reduced MB cell growth and tumor growth in mice that were intracranially injected with MB cells. Consistent with previous research we found that CX-4945 specifically inhibited CK2 and has the ability to cross the blood-brain-barrier. Treatment with CX-4945 also reduced expression of MGMT, a well-known regulator of temozolomide (TMZ) efficacy. Combinatorial treatments with CX-4945 and TMZ had a synergistic effect on MB tumor reduction. Our findings were corroborated when we screened 4,000 FDA approved compounds to identify molecules that work synergistically with CX-4945. TMZ was one of the major compounds that were identified in the screen suggesting that CX-4945 treatment can sensitize MB cells to TMZ by dysregulating MGMT. Together, our findings suggest that CK2 is a novel MB therapeutic target and combining CX-4945 and TMZ can lead to a promising new MB therapy.
Abstract 2796: Coronary Plaque Classification by Multislice Computed Tomography in Comparison with Histopathological Examination of the Atheromatous Tissue Obtained by Directional Coronary Atherectomy
Authors: Shigeki Kimura, Tsunekazu Kakuta, Taishi Yonetsu, Asami Suzuki, Yuki Komatsu, Tetsumin Ri, Mitsuaki Isobe
Journal: Circulation (2008)

Multislice computed tomography (MSCT) has been reported to characterize plaque morphology using intracoronary ultrasound (ICUS) findings as the reference. However, the histopathological assessment for the efficacy of MSCT to distinguish atherosclerotic coronary plaque components has not been performed in vivo. We sought to find the cutoff values of CT density (CTD) to classify the non-calcified plaques using histopathological findings as the standard of reference. Thirty nine target lesions treated by directional coronary atherectomy (DCA) in 39 patients with coronary artery disease, who underwent preintervention MSCT and ICUS, were investigated. The lesions with calcifications in MSCT were excluded. DCA samples of plaques were histopathologically classified into one of the two types; lipid rich plaque (L) or fibrous plaque (F), and further, these two plaque types were subdivided into each two groups, plaque with calcifications or without (L-C, L-NC, F-C, F-NC). The mean CTD was determined by ROI method (5 ROIs) from three cross-sections of each target lesion. We compared the mean CTD among the groups and determined the best cutoff values to differentiate plaque compositions by receiver operating characteristic (ROC) curve. Sixteen lesions were histopathologically classified as lipid rich (6 with calcification (L-C), 10 without (L-NC)) and 23 lesions as fibrous plaque (11: F-C, 12: F-NC). Although mean CTD was not significantly different among the groups (L-C: 73±28 HU, L-NC: 39±11, F-C: 87±15, F-NC: 70±12, p=0.09), there was a significant difference between L-NC and F-NC (p&lt;0.01). ROC analysis revealed that the best cutoff value to differentiate L from F showed relatively low sensitivity (cutoff value 52HU, sensitivity 69%, specificity 96%, AUC 0.82), whereas very high sensitivity and specificity (cutoff value 44 HU, sensitivity 90%, specificity 100%, AUC 0.97) was detected for the cutoff value to differentiate L-NC from F-NC. Plaque CTD may accurately classify non-calcified plaque compositions comparable to histopathological definitions when the lesions were composed without microscopic calcifications.
Pratiques sexuelles et transmission des hépatites A et C
Authors: E Bouvet
Journal: Eurosurveillance (2005)

Dans le present numero d’Eurosurveillance, deux articles rapportent la survenue d’epidemies d’hepatites virales A (a Copenhague) [1] et C (a Paris) [2] dans la population homosexuelle masculine pour laquelle des pratiques sexuelles specifiques ont ete evoquees comme modalites de transmission. Depuis des decennies, il est admis que le virus de l’hepatite A (VHA) se transmet directement de personne a personne par voie feco-orale ou par l’intermediaire d’aliments contamines (initialement ou lors de la preparation) tandis que celui de l’hepatite C (VHC) est transmis par voie parenterale (par le sang et ses derives). Pour ce qui concerne l’hepatite A, plusieurs epidemies ont deja ete rapportees chez des homosexuels ayant conduit a des recommandations en matiere de vaccination contre l’hepatite A par les autorites sanitaires de plusieurs pays [3,4].
P3.13-014 Prediction of Survival with 18F-FDG-PET/CT Early during Erlotinib Treatment in NSCLC Patients – a Comparison of Four Evaluation Methods
Authors: J. Fledelius, A. Winther-Larsen, A.A. Khalil, K. Hjorthaug, J. Frøkiær, P. Meldgaard
Journal: Journal of Thoracic Oncology (2017)
Novas Características da rubéola em Espanha: a evidência de uma epidemia
Authors: C Lemos, R Ramirez, M Ordobas, D H Guibert, J C Sanz, L Garcia, J. F. Martinez Navarro
Journal: Eurosurveillance (2004)

Na maior parte da Europa ocidental, a cobertura da vacina contra a rubeola e elevada. Contudo, antes da introducao da vacina na America Latina, a susceptibilidade a rubeola em mulheres em idade reprodutora era de 10 a 25%. Desde 2002 que 41 (93%) paises da America Latina adoptaram a vacina da rubeola. A populacao adulta imigrante em Espanha constitui um grupo de individuos susceptiveis. Em Fevereiro de 2003, o Plano de Eliminacao do Sarampo da Comunidade de Madrid detectou um aumento das notificacoes de rubeola em mulheres nascidas na America Latina. Foi efectuado um estudo descritivo para caracterizar a epidemia. Um caso confirmado consistia num individuo com febre ou exantema e serologia positiva para IgM e habitante em Madrid, entre 1 de Dezembro de 2002 e 31 de Marco de 2003. Foi calculada a taxa de ataque secundaria (SAR) por casa. Foi identificado um total de 19 casos da rubeola, 15 foram confirmados e 4 foram casos provaveis. Quatorze (73,7%) casos correspondiam a mulheres em idade reprodutora. A idade media era de 25,1 anos. Foi diagnosticada uma gravidez, com interrupcao voluntaria. Onze (57.9%) casos eram oriundos do Equador. O tempo medio de residencia em Espanha era de 41 meses. Nenhum dos casos ou dos 54 (78,3%) contactos domesticos tinham sido vacinados contra a rubeola. O SAR era de 9,1%. Este estudo mostrou a disseminacao da rubeola na comunidade de latino-americanos susceptiveis residentes em Madrid. As intervencoes propostas consistiram num programa de vacinacao para imigrantes, numa campanha de educacao para a saude destinada a prevenir a rubeola congenita e num programa de formacao profissional em saude para a gestao de casos.
Cervicovestibular rehabilitation following sport-related concussion
Authors: Kathryn J Schneider, Willem H Meeuwisse, Karen M Barlow, Carolyn A Emery
Journal: British Journal of Sports Medicine (2017)

Dizziness, neck pain and headaches are commonly reported following a sport-related concussion and may persist.1 2 A combination of cervical and vestibular physiotherapy facilitates recovery following sport-related concussion in individuals with ongoing symptoms of dizziness, neck pain and headaches.3 In our randomised controlled trial (RCT), a higher proportion of individuals treated with multimodal physiotherapy were reported to be medically cleared to return to sport (within 8 weeks) than that of individuals who received a control intervention.4 However, the effect of timing of treatment is not currently known.

Here we share the results of the second phase of this RCT, which evaluated the efficacy of multimodal physiotherapy and vestibular rehabilitation compared with rest in individuals with persistent symptoms of dizziness, neck pain and/or headaches following a sport-related concussion. Individuals who had already completed an 8-week period of either multimodal physiotherapy …
ACTR-09. BORON NEUTRON CAPTURE THERAPY WITH THE COMBINATION OF SUCCESSIVE BEVACIZUMAB TREATMENTS FOR RECURRENT MALIGNANT GLIOMAS
Authors: Shin-Ichi Miyatake, Shinji Kawabata, Motomasa Furuse, Naosuke Nonoguchi, Toshihiko Kuroiwa, Natsuko Kondo, Yoshinori Sakurai, Minoru Suzuki, Koji Ono
Journal: Neuro-Oncology (2017)

Recurrent malignant gliomas (RMGs) are difficult to control. We have often used boron neutron capture therapy (BNCT) for RMGs. However, RMG cases generally receive nearly 60 Gy X-ray irradiation prior to BNCT re-irradiation. Despite the selectivity of BNCT, brain radiation necrosis (BRN) may develop and cause severe neurological sequelae and sometimes death. Recently bevacizumab has been used to treat BRN. We herein used bevacizumab after BNCT for RMG to confer protection against or ameliorate BRN; the bevacizumab treatment was continued as long as possible, and its feasibility (occurrence of any adverse events) and efficacy (overall survival (OS) and progression free survival (PFS)), and BRN control of this combination treatment were evaluated. Seven patients with RMGs (4 grade 4 and 3 grade 3) were treated with BNCT between June 2013 and May 2014, followed by successive bevacizumab treatments. They were followed-up to December 2016. Median OS and PFS after the BNCT and bevacizumab combination treatment were 15.1 and 5.4 months, respectively. In one case, uncontrollable brain edema occurred and ultimately led to death after bevacizumab was interrupted due to meningitis after BNCT. Also in the other, symptomatic aggravation of BRN occurred after interruption of bevacizumab treatment. No BRN was observed during the observation period in the other cases. CTCAE grade 2 proteinuria occurred in two cases and necessitated the interruption of bevacizumab treatments. BNCT followed by bevacizumab treatments well-prevented or well-controlled BRN with prolonged OS and acceptable incidence of adverse events in RMG cases.
L’impact des vagues de chaleur de l’été 2003 sur la mortalité dans quatre villes italiennes
Authors: P Michelozzi, F de Donato, L Bisanti, A Russo, E Cadum, M DeMaria, M D'Ovidio, G Costa, C. A. Perucci
Journal: Eurosurveillance (2005)

Le rapport suivant evalue l’impact de la vague de chaleur de 2003 sur le taux de mortalite par cause et le role des caracteristiques demographiques et des conditions socioeconomiques susceptibles d’avoir augmente le risque de mortalite dans quatre villes italiennes : Bologne, Milan, Rome et Turin. 
Un decompte quotidien de la mortalite a ete effectue pour la population permanente, par âge, sexe et cause du deces. La difference entre le nombre observe et le nombre moyen ajuste de deces a permis de calculer l’exces journalier de mortalite. L’impact de la chaleur sur la sante est mesure en termes de temperature maximale apparente. 
L’exces de mortalite le plus important a ete observe dans le nord ouest de l’Italie (+23% a Turin et Milan). Les personnes âgees (75-84 ans) et tres âgees (85 ans et plus) etaient les groupes d’âge les plus affectes, et la stratification par sexe a montre un accroissement de la mortalite plus prononce chez les femmes. A Rome, l’exces de mortalite le plus eleve (+17,8%) a affecte les personnes les plus demunies, et a Turin les personnes ayant les niveaux d’education les plus bas (+43%).
L’analyse du taux de mortalite par cause confirme les resultats d’etudes precedentes sur l’augmentation de la mortalite liee a la chaleur dans les maladies respiratoires et cardio-vasculaires, et montre egalement un exces de mortalite significatif dans le cas d’affections du systeme nerveux central et de troubles metaboliques/endocriniens. 
Les resultats de 2003 soulignent la necessite de cibler les sous-groupes susceptibles identifies dans les futurs programmes de prevention. La mise en place de systemes d’alerte conjointement a des programmes de prevention efficaces et a la surveillance de la mortalite pendant les vagues de chaleur peuvent representer un outil valable pour la diminution du nombre de deces lies a la chaleur.
P1.05-021 Are Prognostic Factors Different from That Which Predicts Recurrence in Completely Resected Pathological Stage IB Adenocarcinoma?
Authors: H. Ito, H. Nakayama, T. Nagashima, J. Samejima, J. Osawa, K. Inafuku, M. Nito, K. Yamada, T. Yokose
Journal: Journal of Thoracic Oncology (2017)
P1.07-024 ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 Inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors
Authors: W. Park, D. Kwon, A. Desai, V. Florou, D. Saravia, J. Warsch, Y.K. Chae, A. Ishkanian, M. Jahanzeb, R. Mudad, G. Lopes
Journal: Journal of Thoracic Oncology (2017)
Abstract 12859: Prognostic Value of Neutrophil to Lymphocyte Ratio in Acute Decompensated Heart Failure With Reduced or Preserved Left Ventricular Ejection Fraction
Authors: Takahisa Yamada, Takashi Morita, Yoshio Furukawa, Shunsuke Tamaki, Yusuke Iwasaki, Masato Kawasaki, Atsushi Kikuchi, Takumi Kondo, Masashi Ishimi, Hideyuki Hakui, Tatsuhisa Ozaki, Yoshihiro Satoh, Yoshihiro Satoh, Masahiro Seo, Iyo Ikeda, Iyo Ikeda, Eiji Fukuhara, Masatake Fukunami
Journal: Circulation (2015)

Backgrounds: Neutrophil-to-lymphocyte ratio (NLR) has recently emerged as a measure of inflammation and as a prognosticating biomarker in various medical conditions ranging from infectious disease to cardiovascular disease. The prognostic significance of NLR in patients admitted with acute decompensated heart failure (ADHF) is not established. The aim of this study was to investigate the prognostic impact of NLR in ADHF patients, relating to reduced or preserved left ventricular ejection fraction (HFrEF or HFpEF). Methods and Results: We studied 264 patients admitted with ADHF and discharged with survival (HFrEF(LVEF&lt;50%); n=144, HFpEF(LVEF≥50%;n=120). There was no significant difference in NLR at the discharge between patients with HFrEF (2.1±1.1) and HFpEF (2.1±1.0). During a follow up period of 4.2±3.2 yrs, 87 pts died. NLR was significantly associated with mortality in patients with HFrEF (p&lt;0.0001) and HFpEF (p=0.006) at univariate Cox analysis. All cause-death was significantly frequently observed in patients with the highest tertile of NLR (&gt;2.2) than those with the middle or lowest tertile of NLR(&lt;1.5) in patients with HFrEF (60% vs 36% vs 20%, p&lt;0.0001, respectively) and HFpEF (43% vs 20% vs 14%, p=0.004, respectively). After adjustment for baseline characteristics, echocardiographical findings, and blood tests such as hemoglobin, sodium level and estimated glomerular filtration rate, NLR remained a significant independent predictor for mortality in patients with HFrEF (hazard ratio: 1.23 [95%CI 1.04-1.54], p=0.017), while NLR tended to be a independent predictor in those with HFpEF (hazard ratio:1.29 [95%CI 0.98-1.71], p=0.07). Conclusion: NLR at the discharge provides a prognostic value for the prediction of total mortality in ADHF patients with HFrEF and HFpEF, although the prognostic significance of NLR in patients with HFpEF was weakened by adjustment for relevant covariates.
MNGI-07. RED BLOOD CELL TRANSFUSIONS FOLLOWING RESECTION OF SKULL BASE MENINGIOMAS: RISK FACTORS AND CLINICAL OUTCOMES
Authors: Carlito Lagman, John Sheppard, Thien Nguyen, Joel Beckett, Alexander Tucker, Daniel Nagasawa, Bilwaj Gaonkar, Alyssa Ziman, Isaac Yang
Journal: Neuro-Oncology (2017)

Red blood cell transfusion (RBCT) is used in a variety of capacities in neurosurgical practice, but risk factors for RBCT and clinical outcomes have not been described. To advance clinical understanding of blood transfusion in neurosurgery. We retrospectively reviewed adult patients who underwent resection of a meningioma at a single academic medical center and identified patients who had skull base meningiomas. Patients who were postoperatively transfused at least one unit of packed red blood cells (pRBCs) were compared to patients who were not transfused with pRBCs. One hundred and ninety-three patients underwent craniotomy for resection of a meningioma. Thirty-seven patients had non-recurrent skull base meningiomas. Seven of those patients received pRBCs after surgery. Skull base meningiomas were significantly associated with an increased risk of transfusion compared to non-skull base meningiomas (OR 3.89; 95% CI 1.34, 11.25). Meningioma size greater than 4.64 cm (OR 75; 95% CI 5.80, 970.66) and operative time greater than 10 hours (OR 16.25; 95% CI 2.32, 114.06) were significantly associated with an increased risk of transfusion. No adverse transfusion reactions were observed. Transfusion was associated with an increased risk of hospital stay greater than 14 days (OR 38.67; 95% CI 3.20, 467.74) and non-routine discharge (OR 11.30; 95% CI 1.37, 92.72). Skull base meningioma size greater than 4.64 cm and operative time greater than 10 hours were associated with an increased risk of RBCT but those effects did not appear to impact complication rate, hospital stay, or discharge disposition.
P3.07-002 Blocking of ADAM17 Mitigates Kras-Induced Lung Adenocarcinoma Possibly via Inhibition of IL-6 Trans-Signaling
Authors: M. Saad, S. Alhayyani, L. Mcleod, C. Garbers, S. Rose-John, S. Ruwanpura, B. Jenkins
Journal: Journal of Thoracic Oncology (2017)